{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:12:13Z","timestamp":1790712733990,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006190","name":"Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Forschung, Technologie und Raumfahrt","doi-asserted-by":"publisher","award":["03KA1830"],"award-info":[{"award-number":["03KA1830"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.jgar.2026.08.032","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:51:57Z","timestamp":1788796317000},"page":"78-88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["In vitro activity of flomoxef, fosfomycin, and amikacin versus a global panel of third-generation cephalosporin-resistant Enterobacterales and prediction of their ability in pairwise combinations to work as carbapenem-sparing regimens"],"prefix":"10.1016","volume":"51","author":[{"given":"Thea","family":"Brennan-Krohn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4319-0647","authenticated-orcid":false,"given":"Ma\u00eblle","family":"Duffey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Hawser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1367-0276","authenticated-orcid":false,"given":"Nimmi","family":"Kothari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Franceschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0249-4000","authenticated-orcid":false,"given":"Renata M.A.","family":"da Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2026.08.032_bib0001","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2026.08.032_bib0002","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12941-023-00638-3","article-title":"\u201cOne Health\u201d perspective on prevalence of co-existing extended-spectrum \u03b2-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae: a comprehensive systematic review and meta-analysis","volume":"22","author":"Ramatla","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.jgar.2026.08.032_bib0003","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00047-19","article-title":"Epidemiology of \u03b2-lactamase-producing pathogens","volume":"33","author":"Bush","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2026.08.032_bib0004","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1128\/CMR.14.4.933-951.2001","article-title":"Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat","volume":"14","author":"Bradford","year":"2001","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.jgar.2026.08.032_bib0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijmm.2013.02.008","article-title":"CTX-M-type \u03b2-lactamases: a successful story of antibiotic resistance","volume":"303","author":"D\u2019Andrea","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.jgar.2026.08.032_bib0006","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/cid\/ciz173","article-title":"A primer on AmpC \u03b2-lactamases: necessary knowledge for an increasingly multidrug-resistant world","volume":"69","author":"Tamma","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2026.08.032_bib0007","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.08.032_bib0008","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41564-021-00870-7","article-title":"Characterization of antimicrobial-resistant gram-negative bacteria that cause neonatal sepsis in seven low- and middle-income countries","volume":"6","author":"Sands","year":"2021","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.jgar.2026.08.032_bib0009","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1371\/journal.pmed.1004179","article-title":"Patterns of antibiotic use, pathogens, and prediction of mortality in hospitalized neonates and young infants with sepsis: a global neonatal sepsis observational cohort study (NeoOBS)","volume":"20","author":"Russell","year":"2023","journal-title":"PLoS Med"},{"key":"10.1016\/j.jgar.2026.08.032_bib0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s40272-021-00465-z","article-title":"Potential antibiotics for the treatment of neonatal sepsis caused by multidrug-resistant bacteria","volume":"23","author":"Darlow","year":"2021","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.jgar.2026.08.032_bib0011","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/jac\/dkac038","article-title":"Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance","volume":"77","author":"Darlow","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.08.032_bib0012","doi-asserted-by":"crossref","first-page":"3349","DOI":"10.1093\/jac\/dkac323","article-title":"Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings","volume":"77","author":"Darlow","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2026.08.032_bib0013","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00293-21","article-title":"Amikacin combined with Fosfomycin for treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance","volume":"65","author":"Darlow","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.08.032_bib0014","unstructured":"EUCAST. Clinical breakpoints and dosing of antibiotics, https:\/\/www.eucast.org\/clinical_breakpoints; 2023 [accessed 17.11.23]."},{"key":"10.1016\/j.jgar.2026.08.032_bib0015","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","year":"2015"},{"key":"10.1016\/j.jgar.2026.08.032_bib0016","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.2147\/IDR.S185670","article-title":"Relation between flomoxef minimum inhibitory concentrations and clinical outcomes of patients treated with flomoxef for Enterobacteriaceae bacteremia","volume":"11","author":"Lee","year":"2018","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2026.08.032_bib0017","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00216-22","article-title":"OXA-48-like \u03b2-lactamases: global epidemiology, treatment options, and development pipeline","volume":"66","author":"Boyd","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2026.08.032_bib0018","doi-asserted-by":"crossref","first-page":"466","DOI":"10.7164\/antibiotics.38.466","article-title":"Synthesis and antibacterial activity of 6315-S, a new member of the oxacephem antibiotic","volume":"38","author":"Tsuji","year":"1985","journal-title":"J Antibiot"},{"key":"10.1016\/j.jgar.2026.08.032_bib0019","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/BF01645536","article-title":"The meaning of the development of flomoxef and clinical experience in Japan","volume":"19","author":"Ito","year":"1991","journal-title":"Infection"},{"key":"10.1016\/j.jgar.2026.08.032_bib0020","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/BF01964256","article-title":"Comparative in vitro activity of the new oxacephem antibiotic, flomoxef (6315-S)","volume":"7","author":"Ruckdeschel","year":"1988","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2026.08.032_bib0021","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.ijantimicag.2015.07.020","volume":"46","author":"Lee","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2026.08.032_bib0022","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/j.cmi.2024.07.017","article-title":"Susceptibility of OXA-48-like-producing enterobacterales to flomoxef","volume":"30","author":"Owen","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.08.032_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.37201\/req\/s03.10.2022","article-title":"Controversies in the management of ESBL-producing enterabacterales. Clinical implications","volume":"35","author":"Maseda","year":"2022","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.jgar.2026.08.032_bib0024","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3389\/fmicb.2019.00833","article-title":"Piperacillin-tazobactam (TZP) resistance in Escherichia coli due to hyperproduction of TEM-1 \u03b2-lactamase mediated by the promoter Pa\/Pb","volume":"10","author":"Zhou","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.jgar.2026.08.032_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00583-18","article-title":"Extensive gene amplification as a mechanism for piperacillin-tazobactam resistance in Escherichia coli","volume":"9","author":"Schechter","year":"2018","journal-title":"MBio"},{"key":"10.1016\/j.jgar.2026.08.032_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1469-0691.2007.01849.x","article-title":"IRT and CMT \u03b2-lactamases and inhibitor resistance","volume":"14","author":"Cant\u00f3n","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.08.032_bib0027","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.cmi.2024.05.014","article-title":"European society of clinical microbiology and infectious diseases guidelines for antimicrobial stewardship in emergency departments (endorsed by European Association of Hospital Pharmacists)","volume":"30","author":"Schoffelen","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jgar.2026.08.032_bib0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2167-1052.S1-007","article-title":"The hollow Fiber infection model for antimicrobial pharmacodynamics and pharmacokinetics","volume":"1","author":"Cadwell","year":"2012","journal-title":"Adv Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jgar.2026.08.032_bib0029","doi-asserted-by":"crossref","first-page":"3947","DOI":"10.1038\/s41467-024-48296-z","article-title":"Assessment of three antibiotic combination regimens against gram-negative bacteria causing neonatal sepsis in low- and middle-income countries","volume":"15","author":"Kakaraskoska Boceska","year":"2024","journal-title":"Nat Commun"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001645?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716526001645?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:47:31Z","timestamp":1790711251000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716526001645"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":29,"alternative-id":["S2213716526001645"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2026.08.032","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of flomoxef, fosfomycin, and amikacin versus a global panel of third-generation cephalosporin-resistant Enterobacterales and prediction of their ability in pairwise combinations to work as carbapenem-sparing regimens","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2026.08.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}